Announcements Trials
Browse Landscape

Status

Completed 70Recruiting 32Active not recruiting 22Terminated 21Unknown 5Not yet recruiting 2Withdrawn 1No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced Breast Cancer (Female) 1

Interventions

nilotinib 4dabrafenib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3Nivolumab 3tazemetostat 2talimogene laherparepvec 2ceritinib 2TIC10 compound 2Suspensions 2Prednisone 2Powders 2Panobinostat 2Melphalan 2Lenalidomide 2Ipilimumab 2Everolimus 2Dexamethasone 2Crizotinib 2Bortezomib 2Bevacizumab 2Axitinib 2zanubrutinib 1zanidatamab 1venetoclax 1veliparib 1tucatinib 1talquetamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Letrozole × Clear all
NCT02142868 2018-12-21

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Pfizer

No longer available
Breast

Advanced Breast Cancer (Female)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡